ImmunityBio
IBRX
IBRX
270 hedge funds and large institutions have $338M invested in ImmunityBio in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 98 increasing their positions, 63 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
4% less capital invested
Capital invested by funds: $352M → $338M (-$14M)
32% less call options, than puts
Call options by funds: $6.46M | Put options by funds: $9.55M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
270
Holding in Top 10
1
Calls
$6.46M
Puts
$9.55M
Top Buyers
| 1 | +$13.1M | |
| 2 | +$11.6M | |
| 3 | +$11.6M | |
| 4 |
Goldman Sachs
New York
|
+$11.4M |
| 5 |
Two Sigma Investments
New York
|
+$4.78M |
Top Sellers
| 1 | -$16.2M | |
| 2 | -$5.15M | |
| 3 | -$4.19M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.81M |
| 5 |
SPS
Susquehanna Portfolio Strategies
Bala Cynwyd,
Pennsylvania
|
-$968K |
